echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xi'an Jansen released 4 years of clinical data on Tremfya psoriasis Skin removal rate remained high.

    Xi'an Jansen released 4 years of clinical data on Tremfya psoriasis Skin removal rate remained high.

    • Last Update: 2020-08-20
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On June 15, Xi'an Jansen Pharmaceuticals released the latest data from VOYAGE 2, a long-term clinical trial of Tremfya (guselkumab) for patients with plaque yandr.
    results showed that Tremfya showed good consistency and high skin removal rates at two time baselines at 100 weeks and 204 weeks (four years).
    in open-label extended trial VOYAGE 2, 80 percent of patients treated with 100mg Tremfya every 8 weeks achieved an improvement in psoriasis area and severity index by more than 90% in the fourth year; 82% of patients achieved a researcher's global assessment (IGA) score of 0 (for removal) or 1 (for mild disease); 51% of patients reached PASI 100 or completely removed psoriasis.
    the data has been received by the American Academy of Dermatose at its annual general meeting and shared online as a poster (P15300).
    the clinical endpoint of VOYAGE 2 also includes patient-reported outcome assessments, including the Skin Disease Quality of Life Index (DLQI) and Psoriasis Symptoms and Signs Diary (PSSD).
    in the fourth year, 69% of patients had a DLQI score of 0 or 1 (obvious skin disease had no effect on health quality of life), 40% had a PSSD symptom score of 0 (asymptomatic state), and 27% had PSSD signs hidden to 0 (no signs).
    in voyage 2 trials, the safety of Tremfya and Adamu monoause is consistent with the safety information provided in the current prescription information. Professor Kristian Reichi, lead researcher of the voyage 2 study,
    , said: "Long-term remission of psoriasis is important for improving the quality of life of patients, and the results of the VOYAGE 2 study show that Tremfya can have therapeutic effects for up to 4 years and provide long-term treatment options for patients with chronic psoriasis. in addition, comparison data on clinical outcomes reported by patients with Thetagain's head-to-head randomized phase 3 clinical trial VOYAGE 1 have been shared via the online poster (P15287).

    results showed that at the 48th week, 42% of the patients in the Tremfya treatment group achieved asymptomatic, i.e. PSSD symptom score was 0, the proportion of Adamu monotodrine group was 23%, and 35% of patients in the Tremfya treatment group achieved atotal, i.e. PSSD sign score was 0, and the Adamu monoantitic group was 19%.
    and during the 48-week treatment, patients in the Tremfya treatment group had no symptoms such as itching, pain, cracking or scaly skin for longer than the Adamu monotomatism group.
    Reference Source: New Phase 3 Data for TREMFYA® , a First-in-Class IL-23 p19 Subunit Put, Show Consistent, High Levels of The Rand Son Son S.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.